dihexa derived from angiotensin iv Frontiers | Angiotensin-II-derived reactive oxygen

[4] Zhou H, et al

Both fall within the range that studies show can be effectively delivered intranasally, though the smaller BPC-157 may achieve somewhat higher bioavailability through this route

This is why results might seem hit-or-miss at first

Phase 1 study dosing: Doses tested: 100 mcg to 1000 mcg daily Route: subcutaneous injection Results: dose-proportional effects on fat loss Safety: all doses well tolerated Phase 2 study dosing: Doses tested: 300 mcg to 600 mcg daily Route: once- or twice-daily subcutaneous injection Duration: 12 weeks typical Results: significant fat loss at all doses, with 500600 mcg showing the best efficacy Research Dosage Guidelines Based on available clinical data, research protocols generally consider the following ranges